Category - Markets

Leerink Partners launched coverage of Millendo Therapeutics (NASDAQ:MLND) with an “outperform” rating and $24 price target. The stock closed at $9.64 on Dec. 12. Millendo is developing treatments for rare, debilitating...

H.C. Wainwright analyst Ed Arce assumed coverage of Organovo Holdings (NASDAQ:ONVO) with a “buy” rating and price target of $2.50. The stock closed at $1.04 on Dec. 12. Organovo was founded in 2007 as a CRO, offering...

AGP/Alliance Global Partners initiated coverage of DarioHealth (NASDAQ:DRIO) with a “buy” rating and price target of $2.50. The stock closed at 76 cents on Dec. 12. ”DarioHealth is well positioned at the confluence of...

Maxim Group raised its price target for Quantum Genomics SA (Euronext Growth – FR0011648971 – ALQGC) to €9 from €6 after the company held a recent key opinion leader and investor day. The stock closed at €5...

Analysts at Canaccord Genuity and BTIG launched coverage of Vapotherm (NYSE:VAPO) with “buy” ratings and price targets of $25 and $26, respectively. The stock closed at $20.93 on Dec. 7. Vapotherm sells Precision Flow...

Stifel downgraded Conatus Pharmaceuticals (NASDAQ:CNAT) to “hold” from “buy” and slashed its price target to $4 from $10 after the company’s ENCORE-PH trial missed its pre-specified primary endpoint. The stock closed at...

Echelon Wealth Partners upgraded ProMetic Life Sciences (TSX:PLI) to “speculative buy” from “hold” but reduced its price target to 60 cents from $1 after the company announced plans for Phase 3 testing of its anti...

Roth Capital Partners initiated coverage of BioSig Technologies (NASDAQ:BSGM) with a “buy” rating and $14 price target. The stock closed at $3.97 on Dec. 4. BioSig is a medical device company developing the PURE EP...

Roth Capital Partners launched coverage of CorMedix (NASDAQ:CRMD) with a “buy” rating and price target of $6. The stock closed at $1.35 on Dec. 4. CorMedix is developing Neutrolin for the prevention of catheter-related...

BTIG initiated coverage of Valeritas Holdings (NASDAQ:VLRX) with a “buy” rating and price target of $1. The stock closed at 39 cents on Dec. 3. Valeritas sells V-Go, the only pump on the market for Type 2 diabetes...